Preprint Review Version 1 This version is not peer-reviewed

The Role of Gene Therapy in Premature Ovarian Insufficiency Management

Version 1 : Received: 9 September 2018 / Approved: 12 September 2018 / Online: 12 September 2018 (11:06:42 CEST)

A peer-reviewed article of this Preprint also exists.

Atabiekov, I.; Hobeika, E.; Sheikh, U.; El Andaloussi, A.; Al-Hendy, A. The Role of Gene Therapy in Premature Ovarian Insufficiency Management. Biomedicines 2018, 6, 102. Atabiekov, I.; Hobeika, E.; Sheikh, U.; El Andaloussi, A.; Al-Hendy, A. The Role of Gene Therapy in Premature Ovarian Insufficiency Management. Biomedicines 2018, 6, 102.

Journal reference: Biomedicines 2018, 6, 102
DOI: 10.3390/biomedicines6040102

Abstract

Premature ovarian insufficiency (POI) is a highly prevalent disorder, characterized by the development of menopause before age of 40. Most cases are idiopathic; however, in some women the cause of this condition (e.g. anticancer treatment, genetic disorders, and enzymatic defects) may be identified. Although hormone replacement therapy, the principal therapeutic approach for POI, helps to alleviate the related symptoms, this does not effectively solve the issue of fertility. Assisted reproductive techniques also lack efficacy in these women. Thus, the effective approach to manage the patients with POI is highly warranted. Several mechanisms, associated with POI, have been identified, including lack of FSH receptor functioning, alterations in the apoptosis control, mutations in Sal-like 4 genes, thymulin or basonuclin-1 deficiency etc. The above-mentioned may be good targets for gene therapy in order to correct defects, leading to POI. The goal of this review is to summarize the current experience on the POI studies, that employed gene therapy, and to discuss the possible future directions in this field.

Subject Areas

Premature ovarian insufficiency, POI; Gene therapy; Menopause; SAL-like 4 genes, SALL4; Follicle-stimulating hormone (FSH); Basonuclin-1; Replication-incompetent adenoviral vector, Ad; Stem cells, SC.

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.